Ironwood Pharmaceuticals 2025 Outlook: Expects Revenue Of $260M–$290M Vs. $287.583M Est., Sees Adjusted EBITDA Above $85M

Benzinga02-27
  • Ironwood 2025 Financial Guidance. Ironwood continues to expect:
 

2025 Guidance

(February 2025)

U.S. LINZESS Net Sales

$800 - $850 million

High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign

Total Revenue1$260 - $290 million
Adjusted EBITDA2>$85 million
1 Ironwood's U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood's commercial expenses related to sales of LINZESS in the U.S. The FY2025 total revenue guidance accounts for the impact of the reduction to Ironwood's commercial expenses and corresponding reimbursement from AbbVie due to Ironwood's strategic reorganization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment